博拓生物(688767) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥121,621,909.77, representing a year-over-year increase of 21.42%[2] - The net profit attributable to shareholders for Q3 2024 was ¥17,036,624.18, a decrease of 43.07% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,043,983.72, down 51.08% year-over-year[2] - The basic earnings per share for Q3 2024 was ¥0.16, reflecting a decline of 42.86% compared to the previous year[2] - Net profit for the third quarter of 2024 was ¥86,639,188.86, a decrease of 3.2% from ¥90,060,965.64 in the previous year[22] - Earnings per share (EPS) for the third quarter was ¥0.85, slightly down from ¥0.86 in the same quarter of 2023[23] - The total comprehensive income for the third quarter was ¥84,847,856.97, down from ¥91,077,493.36 in the previous year[23] Research and Development - Research and development expenses totaled ¥13,584,882.99, a decrease of 10.37% from the same period last year, accounting for 11.17% of operating revenue[4] - Research and development expenses for the first three quarters were ¥43,944,660.52, nearly unchanged from ¥43,745,658.93 in 2023[20] - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the report[15] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,529,728,300.75, a decrease of 1.93% from the end of the previous year[4] - The company's total equity as of the end of the third quarter was ¥2,378,771,213.68, down from ¥2,420,749,376.36 in the previous year[18] - Total liabilities decreased to ¥150,957,087.07 from ¥158,820,879.74 year-over-year, reflecting a reduction of approximately 5.4%[18] - The company's total assets stood at CNY 2.53 billion, a slight decrease of 1.9% from CNY 2.58 billion at the end of 2023[16] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥109,018,080.05, an increase of 198.76% compared to the same period last year[2] - In the first three quarters of 2024, the cash inflow from operating activities reached ¥443,941,977.02, an increase of 9.8% compared to ¥404,508,892.26 in the same period of 2023[25] - The net cash flow from operating activities for the first three quarters of 2024 was ¥109,018,080.05, significantly up from ¥36,490,523.60 in 2023, marking an increase of 198.5%[25] - The cash inflow from investment activities in the first three quarters of 2024 was ¥3,612,605,046.36, a substantial rise from ¥124,244,810.35 in 2023[26] - The net cash flow from investment activities for the first three quarters of 2024 was -¥268,489,208.72, compared to a positive cash flow of ¥107,005,914.12 in 2023[26] - The net cash flow from financing activities for the first three quarters of 2024 was -¥127,195,428.01, compared to -¥236,743,434.40 in 2023, indicating an improvement[26] Shareholder Information - The company reported a total of 7,239 common shareholders at the end of the reporting period[9] - The company has a total of 24,896,000 shares held by Hangzhou Tuokang Investment Co., Ltd., representing 23.5% of the total shares[12] - The top five shareholders collectively hold 62.5% of the company's shares, indicating a high level of ownership concentration[12] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[14] Future Outlook - Future outlook remains cautiously optimistic, with a focus on market expansion and potential strategic acquisitions[15]